- Home
- Publications
- Publication Search
- Publication Details
Title
Novel IDH1-Targeted Glioma Therapies
Authors
Keywords
-
Journal
CNS DRUGS
Volume 33, Issue 12, Pages 1155-1166
Publisher
Springer Science and Business Media LLC
Online
2019-11-25
DOI
10.1007/s40263-019-00684-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
- (2019) Felipe J. Núñez et al. Science Translational Medicine
- Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
- (2019) Bin Fan et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
- (2019) Atsushi Natsume et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
- (2019) Danielle Golub et al. Frontiers in Oncology
- Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma
- (2019) Makoto Nakagawa et al. ONCOGENE
- IDH1/2Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
- (2018) Remco J. Molenaar et al. CLINICAL CANCER RESEARCH
- Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
- (2018) Fangrui Wu et al. Medicinal Chemistry
- An inhibitor of oxidative phosphorylation exploits cancer vulnerability
- (2018) Jennifer R. Molina et al. NATURE MEDICINE
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
- (2018) Lukas Bunse et al. NATURE MEDICINE
- Wild-type and mutated IDH1/2 enzymes and therapy responses
- (2018) Remco J. Molenaar et al. ONCOGENE
- Mutant IDH1 Promotes Glioma Formation In Vivo
- (2018) Beatrice Philip et al. Cell Reports
- Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
- (2018) Samuel K. McBrayer et al. CELL
- BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
- (2018) Delphine Merino et al. CANCER CELL
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
- (2018) Ingo Mellinghoff et al. NEURO-ONCOLOGY
- RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA
- (2018) Ingo Mellinghoff et al. NEURO-ONCOLOGY
- Therapeutic targeting of isocitrate dehydrogenase mutant AML
- (2017) Prajwal Boddu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- EXTH-34. COMBINED USE OF THE PAN-IDH MUTANT INHIBITOR AG-881 WITH RADIATION THERAPY SHOWS ADDED BENEFIT IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
- (2017) Brandon Nicolay et al. NEURO-ONCOLOGY
- ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
- (2017) Ingo K Mellinghoff et al. NEURO-ONCOLOGY
- Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
- (2017) Georg Karpel-Massler et al. Nature Communications
- Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
- (2017) Daniel J. Urban et al. Scientific Reports
- Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis
- (2016) Chiara Bardella et al. CANCER CELL
- Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
- (2016) S. K. Saha et al. Cancer Discovery
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
- (2015) Kensuke Tateishi et al. CANCER CELL
- Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells
- (2015) Lucas B. Sullivan et al. CELL
- 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling
- (2015) Xudong Fu et al. Cell Metabolism
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
- (2015) Pu Wang et al. Cell Reports
- Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
- (2014) Jinlong Shi et al. TUMOR BIOLOGY
- What do we know about IDH1/2 mutations so far, and how do we use it?
- (2013) Craig Horbinski ACTA NEUROPATHOLOGICA
- ABT-199: Taking Dead Aim at BCL-2
- (2013) Matthew S. Davids et al. CANCER CELL
- Structure-guided design of a selective BCL-XL inhibitor
- (2013) Guillaume Lessene et al. Nature Chemical Biology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation
- (2012) Sichen Li et al. NEURO-ONCOLOGY
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- An in vivo patient-derived model of endogenous IDH1-mutant glioma
- (2011) H. A. Luchman et al. NEURO-ONCOLOGY
- PHGDH amplification and altered glucose metabolism in human melanoma
- (2011) Edouard Mullarky et al. Pigment Cell & Melanoma Research
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
- (2010) Stefan Gross et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now